Status:

COMPLETED

Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure

Lead Sponsor:

Vanderbilt University Medical Center

Conditions:

Heart Failure

Eligibility:

All Genders

30-65 years

Brief Summary

The incidence of heart failure grows as the population continues to age. Heart failure incidence approaches 10 per 1,000 persons after the age of 65. Although pharmacotherapy improves the treatment of...

Detailed Description

Heart failure remains a devastating progressive chronic disease in which pharmacotherapy is not often sufficient. Although cell based therapy is gaining publicity in the treatment of coronary artery d...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Subjects 30-65 years old.
  • Subjects able to give Informed Consent.
  • Subjects who will give permission for collection of clinical and demographic data from the electronic medical records.
  • Subjects with symptomatic ischemic or non-ischemic heart failure in a stable condition with New York Heart Association class II-III for at least the last 3 months before study enrollment.
  • Left ventricular ejection fraction (LVEF) \< 40%.
  • Peak volume of oxygen utilization (peak VO2) of \< 25 ml/kg/min.
  • Patient on a stable dose of statin or who can be initiated on statin therapy.
  • Subjects with ischemic cardiomyopathy must have had either a negative stress test within the last 6 months or a cardiac catheterization within the last year confirming stable disease.
  • Exclusion criteria:
  • Subjects with myocardial infarction or unstable angina within the last six months.
  • Subjects with symptomatic or severe aortic stenosis.
  • Subjects with severe HTN (SBP \> 180) or hypotension (SBP \< 100).
  • Subjects who are pregnant.
  • Subjects who have bone marrow suppression.
  • Subjects with exercise limiting peripheral arterial disease.
  • Subjects with history of ventricular tachycardia without an implantable defibrillator
  • Subjects with decompensated diabetes (HgA1c \>10).
  • Subjects with orthopedic limitations.
  • Subjects with any other clinical condition precluding regular participation in walking exercise regimen.
  • Subjects who already participate in regular physical exercise regimen for greater than 30 minutes a day 5 days per week.

Exclusion

    Key Trial Info

    Start Date :

    July 1 2009

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2014

    Estimated Enrollment :

    9 Patients enrolled

    Trial Details

    Trial ID

    NCT00937443

    Start Date

    July 1 2009

    End Date

    January 1 2014

    Last Update

    April 4 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Vanderbilt Heart and Vascular Institute

    Nashville, Tennessee, United States, 37232-8802